HK1211235A1 - Methods of treating cancer and preventing drug resistance - Google Patents

Methods of treating cancer and preventing drug resistance

Info

Publication number
HK1211235A1
HK1211235A1 HK15112149.8A HK15112149A HK1211235A1 HK 1211235 A1 HK1211235 A1 HK 1211235A1 HK 15112149 A HK15112149 A HK 15112149A HK 1211235 A1 HK1211235 A1 HK 1211235A1
Authority
HK
Hong Kong
Prior art keywords
methods
treating cancer
drug resistance
preventing drug
preventing
Prior art date
Application number
HK15112149.8A
Other languages
Chinese (zh)
Inventor
Debasish Raha
Jeffrey Settleman
Timothy R Wilson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201361768253P priority Critical
Priority to US201361834317P priority
Priority to PCT/EP2014/053377 priority patent/WO2014128235A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1211235A1 publication Critical patent/HK1211235A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
HK15112149.8A 2013-02-22 2015-12-09 Methods of treating cancer and preventing drug resistance HK1211235A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201361768253P true 2013-02-22 2013-02-22
US201361834317P true 2013-06-12 2013-06-12
PCT/EP2014/053377 WO2014128235A1 (en) 2013-02-22 2014-02-21 Methods of treating cancer and preventing drug resistance

Publications (1)

Publication Number Publication Date
HK1211235A1 true HK1211235A1 (en) 2016-05-20

Family

ID=50179591

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112149.8A HK1211235A1 (en) 2013-02-22 2015-12-09 Methods of treating cancer and preventing drug resistance

Country Status (9)

Country Link
EP (1) EP2958592A1 (en)
JP (1) JP2016509045A (en)
KR (1) KR20150118159A (en)
CN (1) CN104994879A (en)
BR (1) BR112015018418A2 (en)
CA (1) CA2900097A1 (en)
HK (1) HK1211235A1 (en)
MX (1) MX2015010791A (en)
WO (1) WO2014128235A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015059677A1 (en) * 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
WO2016168150A2 (en) * 2015-04-13 2016-10-20 The Board Of Regents Of The University Of Texas System Treatment for cancer metastasis
WO2019098288A1 (en) * 2017-11-15 2019-05-23 学校法人 慶應義塾 Antitumor agent and compounding agent
KR20190056758A (en) 2017-11-17 2019-05-27 주식회사 지뉴브 Combination therapy for treating cancers characterized by having cancer stem cells

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
WO1984003506A1 (en) 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
EP1186660A3 (en) 1985-03-30 2002-03-20 KAUFFMAN, Stuart A. Method for obtaining DNA, RNA, peptides, polypeptides or proteins by means of a DNA-recombination technique
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035D0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
AT102631T (en) 1988-11-11 1994-03-15 Medical Res Council Cloning of immunoglobulin sequences from the variabelen domains.
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag Bispecific, oligo, mono- and oligovalent antikoerperkonstrukte, their production and use
DE69025946T2 (en) 1989-09-08 1996-10-17 Univ Johns Hopkins Modifications to the structure of the EGF receptor gene in human glioma
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770434A (en) 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
AU668347B2 (en) 1990-11-21 1996-05-02 Torrey Pines Institute For Molecular Studies Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
DE69129154D1 (en) 1990-12-03 1998-04-30 Genentech Inc A method for enrichment of protein variants with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッドGenentech,Inc. Immunoglobulin mutant
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JPH08500962A (en) 1992-02-06 1996-02-06 クリエイティブ バイオモレキュルズ,インコーポレイテッド Cancer marker for biological synthetic binding protein
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
DE69428764D1 (en) 1993-12-24 2001-11-29 Merck Patent Gmbh immunoconjugates
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248D0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
CU22545A1 (en) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtaining a chimeric and humanized antibody against the epidermal growth factor receptor for diagnostic and therapeutic use
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
CA2224435C (en) 1995-07-06 2008-08-05 Peter Traxler Pyrrolopyrimidines and processes for the preparation thereof
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1997038983A1 (en) 1996-04-12 1997-10-23 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
PT912559E (en) 1996-07-13 2003-03-31 Glaxo Group Ltd Heterocyclic compounds fused as protein inhibitors tyrosine kinase
ID18494A (en) 1996-10-02 1998-04-16 Novartis Ag Pirazola derivative fused and the manufacturing process
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7165698A (en) 1997-05-06 1998-11-27 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1998058964A1 (en) 1997-06-24 1998-12-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AT419009T (en) 1997-10-31 2009-01-15 Genentech Inc Methods and compositions consisting of glycoprotein glycoforms
WO1999024037A1 (en) 1997-11-06 1999-05-20 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
BR9813365A (en) 1997-12-05 2004-06-15 Scripps Research Inst Method for the production and humanisation of a mouse monoclonal antibody
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
ES2532910T3 (en) 1998-04-02 2015-04-01 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
DE69904358T2 (en) 1998-11-19 2003-04-17 Warner Lambert Co N- 4- (3-chloro-4-fluoro-phenylamino) -7- (3-morfolin-4-yl-propoxy) -quinazolin-6-yl -akrylamid, an irreversible tyrosine kinases inhibitor
CA2355215A1 (en) 1998-12-28 2000-07-06 Jim Wells Identifying small organic molecule ligands for binding
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (en) 1999-01-15 2011-08-31 Genentech, Inc. Polypeptide variants with altered effector function
EP1914244B1 (en) 1999-04-09 2013-05-29 Kyowa Hakko Kirin Co., Ltd. Method of modulating the activity of functional immune molecules
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
SK287401B6 (en) 1999-11-05 2010-09-07 Astrazeneca Ab Quinazoline derivatives, process for preparing the same and pharmaceutical composition containing the same and the use of them
CA2393869A1 (en) 1999-12-15 2001-06-21 Genetech,Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
NZ518764A (en) 1999-12-29 2004-02-27 Immunogen Inc Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
ES2637801T3 (en) 2000-04-11 2017-10-17 Genentech, Inc. multivalent antibodies and uses thereof
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU3942202A (en) 2000-11-30 2002-06-11 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
AU2002339845B2 (en) 2001-08-03 2009-03-26 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JP4628679B2 (en) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Cells in which the activity of protein decreased or deleted that are involved in the transport of Gdp- fucose
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
WO2003102157A2 (en) 2002-06-03 2003-12-11 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
PT1454992E (en) 2003-03-07 2006-09-29 Ist Naz Stud Cura Dei Tumori Kinase-test of anaplastic lymphoma, reagents and compositions
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc Antibodies directed to c-MET
DK2287156T3 (en) 2003-08-15 2013-08-26 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory disorders and disorders of the immune system
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
JPWO2005035778A1 (en) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α1,6- fucosyltransferase preparation of antibody composition functions using an RNA that suppresses the glycosyl transferase
NZ547589A (en) 2003-11-05 2009-05-31 Glycart Biotechnology Ag CD20 antibodies with increased Fc receptor binding affinity and effector function
CN103394083B (en) 2003-11-06 2017-07-18 西雅图基因公司 It can be coupled with a ligand compound monomethyl valine
JPWO2005053742A1 (en) 2003-12-04 2007-06-28 協和醗酵工業株式会社 Pharmaceutical comprising the antibody compositions
WO2005097765A1 (en) 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
MX2007001470A (en) 2004-08-05 2007-03-26 Genentech Inc Humanized anti-cmet antagonists.
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EP1791565B1 (en) 2004-09-23 2016-04-20 Genentech, Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
KR101125919B1 (en) 2005-06-22 2012-06-12 플렉시콘, 인코퍼레이티드 Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors
AT504565T (en) 2005-10-07 2011-04-15 Exelixis Inc Azetidines as mek inhibitors in the treatment of proliferative diseases
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
DK1959955T3 (en) 2005-12-05 2011-02-07 Pfizer Prod Inc A method for the treatment of abnormal cell growth
AU2007245181A1 (en) 2006-03-30 2007-11-08 Novartis Ag Compositions and methods of use for antibodies of c-Met
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US20070292936A1 (en) 2006-05-09 2007-12-20 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2007143090A2 (en) 2006-06-02 2007-12-13 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
KR100829972B1 (en) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 -/ anti-hgf/sf humanized antibody and method for the preparation thereof
US8106004B2 (en) 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
CA2598893C (en) 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
TWI432427B (en) 2006-10-23 2014-04-01 Cephalon Inc Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
NZ590601A (en) 2006-12-08 2011-09-30 Irm Llc Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司;群创光电股份有限公司 Liquid crystal panel drive device and its drive method
US20090175869A1 (en) * 2007-05-31 2009-07-09 Ascenta Therapeutics, Inc. Pulsatile Dosing of Gossypol for Treatment of Disease
TWI389893B (en) 2007-07-06 2013-03-21 Astellas Pharma Inc Di (arylamino) ary1 compound
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
EP2042191B1 (en) 2007-09-28 2013-01-02 Roberto Chiarle Anaplastic Lymphoma Kinase (ALK) as oncoantigen for lymphoma vaccination
EP3061770A1 (en) 2008-01-07 2016-08-31 Amgen, Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2009111277A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors
ES2400202T3 (en) 2008-02-29 2013-04-08 Array Biopharma, Inc. RAF inhibitors of pyrazole [3,4-B] pyridine
WO2009111280A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
WO2009111278A2 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
CA2722326A1 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8124389B2 (en) 2008-05-07 2012-02-28 The Board Of Trustees Of The Leland Stanford Junior University Crystal structure of aldehyde dehydrogenase and methods of use thereof
PA8849001A1 (en) 2008-11-21 2010-06-28 Lilly Co Eli Antibodies c-met
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
EP2287197A1 (en) 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (en) 2009-10-30 2016-11-01 삼성전자 주식회사 c-Met specific antibodies and uses thereof
KR101748707B1 (en) 2009-11-27 2017-06-20 삼성전자주식회사 c-Met specific antibodies and diagnosis kit for cancer using thereof

Also Published As

Publication number Publication date
WO2014128235A1 (en) 2014-08-28
CN104994879A (en) 2015-10-21
KR20150118159A (en) 2015-10-21
EP2958592A1 (en) 2015-12-30
MX2015010791A (en) 2015-11-26
CA2900097A1 (en) 2014-08-28
BR112015018418A2 (en) 2017-07-18
JP2016509045A (en) 2016-03-24

Similar Documents

Publication Publication Date Title
IL240475A (en) Tubulysin compounds, methods of making them and use thereof
EP2986339A4 (en) Nasal stimulation devices and methods
EP2941253A4 (en) Methods for reducing cellular proliferation and treating certain diseases
GB201313363D0 (en) Security devices and method of manufacture
GB2535360B (en) Methods of preparing polyhemiaminals and polyhexahydrotriazines
RU2016109938A (en) Composition and vaccine for treatment of prostate cancer
SG10201801429VA (en) Composition and vaccine for treating lung cancer
GB201803280D0 (en) Modified cells and methods of therapy
IL244254D0 (en) Engineered anti-dll3 conjugates and methods of use
IL239739D0 (en) Methods of treating pancreatic cancer
HK1223246A1 (en) Pain medicine combination and uses thereof
IL246239A (en) Bicyclic heterocycle compounds and their uses in therapy
GB2521738B (en) Tobacco material and treatment thereof
HUE039560T2 (en) Microclosures and related methods for skin treatment
SG11201506979YA (en) Catheter assemblies with wipeable bloodstop and related methods
HK1220405A1 (en) Methods of treating bladder cancer
EP3041470A4 (en) Methods and compositions for selective and targeted cancer therapy
RU2016109811A (en) Cancer treatment by combination of pd-1 antagonist and dynacyclib
GB201320729D0 (en) Therapeutic compounds and their use
EP2968607A4 (en) Cancer vaccines and methods of treatment using the same
EP2818483A4 (en) Medicinal composition for treating and/or preventing cancer
EP2988786A4 (en) Selective drug delivery compositions and methods of use
SG11201510561QA (en) Patient interface and aspects thereof
GB201308959D0 (en) Security documents and methods of manufacture thereof
EP2961475A4 (en) Systems and methods for wireless control of noninvasive electrotherapy